Strategic partnerships Early stage university spin-out with a novel Neo-Islet therapy targeting Type-1 Diabetes and expanding toward Type-2 Diabetes, presenting a compelling collaboration opportunity for contract research, clinical development, and translational partnerships with academic institutions, biotechs, and CROs focusing on regenerative medicine and endocrinology.

Clinical development readiness Completed pre-clinical work and pursuing FDA submission for human trials, plus active canine diabetic trials under INAD, indicating a strong regulatory and translational pathway that may attract CROs, pharma sponsors, and investors seeking opportunities in pioneering cell-based therapies.

Funding and traction Funding history includes $16M raised and revenue in the low millions, signaling a startup with capital and early market validation that could interest strategic investors, grant partnerships, or license deals to accelerate clinical progress and scale manufacturing.

Clinical data leverage Proven Neo-Islet technology co-aggregates mesenchymal and pancreatic islet cells with published interim safety and efficacy data, offering a tangible value proposition for out-licensing, co-development, or pilot studies with academic medical centers and specialty clinics.

Market positioning Recognition in innovation awards and ADA session exposure, plus a clear roadmap toward outpatient procedures that aim for insulin independence, presenting a differentiator for partnerships with diabetes care platforms, endocrinology networks, and patient advocacy groups to drive adoption and enrollment.